Molecular clusters and precision medicine in pheochromocytomas and paragangliomas
Endocrine-Related Cancer · 01.09.2026 · 33 (9)
DOI: 10.1530/erc-26-0258 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, online erschienen am 21.08.2026. Verfasst von Madson Q Almeida und 2 weiteren Autor:innen. Beteiligte Einrichtung: Unidade de Adrenal, Laboratório de Endocrinologia Molecular e Celular LIM25, Divisão de Endocrinologia e Metabologia, Hospital das Clínicas, Faculdad…. Hauptthemen laut MEDLINE: Paraganglioma, Pheochromocytoma, Precision Medicine, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben.
Abstract (Originalsprache)
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors derived from chromaffin cells of the adrenal medulla and extra-adrenal paraganglia. Over the past two decades, the genomic characterization of PPGLs has profoundly transformed their diagnosis, classification, risk stratification, and therapeutic management. Up to 40% of PPGLs harbor germline pathogenic variants, the highest proportion among human neoplasms, and somatic driver events are identified in a substantial fraction of the remaining cases. Integrative multi-omic studies have established three main molecular clusters: a pseudohypoxic cluster driven by Krebs-cycle alterations (SDHx, FH, MDH2, DLST) and HIF-2α pathway alterations (VHL, EPAS1, EGLN1/2); a kinase-signaling cluster driven by activation of RAS/MAPK and PI3K/AKT pathways (RET, NF1, HRAS, TMEM127, MAX); and a Wnt-signaling cluster characterized primarily by MAML3 fusions. This review summarizes progress in PPGL genomics, highlighting geographic and sex-related particularities. Using EPAS1/HIF-2α and RET as paradigmatic examples, we illustrate how diverse germline, somatic, mosaic, and fusion events converge on common core signaling hubs that can be therapeutically exploited with FDA-approved selective inhibitors for relevant targets (e.g. belzutifan for HIF-2α; selpercatinib and pralsetinib for RET). We further review the genomic determinants of metastatic risk (SDHB, ATRX, TERT, and MAML3 fusions), the immune microenvironment of metastatic disease, and emerging radionuclide theranostics, liquid biopsy biomarkers, and integrative multi-omic approaches that are reshaping precision medicine for PPGLs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unidade de Adrenal, Laboratório de Endocrinologia Molecular e Celular LIM25, Divisão de Endocrinologia e Metabologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo , São Paulo, Brazil.
- Unidade de Oncologia Endócrina, Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo , São Paulo, Brazil.
- Division of Hematology and Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio (UTHSA) , San Antonio, Texas, USA.
- Mays Cancer Center UTHSA , San Antonio, Texas, USA.
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) , Madrid, Spain.
- Hereditary Endocrine Cancer Group, Cancer Genomics Program, Spanish National Cancer Research Centre (CNIO) , Madrid, Spain.
ORCID-Profile: Madson Q Almeida, Patricia L M Dahia, Mercedes Robledo
Zitieren
APA
Almeida, M. Q., Dahia, P. L. M., & Robledo, M. (2026). Molecular clusters and precision medicine in pheochromocytomas and paragangliomas. Endocrine-Related Cancer, 33(9). https://doi.org/10.1530/erc-26-0258
Vancouver
Almeida MQ, Dahia PLM, Robledo M. Molecular clusters and precision medicine in pheochromocytomas and paragangliomas. Endocrine-Related Cancer. 2026;33(9). doi:10.1530/erc-26-0258
BibTeX
@article{Almeida2026,
author = {Almeida, Madson Q and Dahia, Patricia L M and Robledo, Mercedes},
title = {Molecular clusters and precision medicine in pheochromocytomas and paragangliomas},
journal = {Endocrine-Related Cancer},
year = {2026},
volume = {33},
number = {9},
doi = {10.1530/erc-26-0258}
}
EUVIMED